Recursion Pharmaceuticals (RXRX) Leerink Global Healthcare Conference 2026 summary

Strategic focus and portfolio management

• Emphasis on three strategic areas: doubling down on proof points, targeted platform investment, and disciplined ambition.

• Rapid go/no-go decisions are made across programs, with a data-driven approach to portfolio management.

• Joint portfolio with Sanofi includes five programs targeting challenging I&I and oncology targets.

• Platform efficiency improvements allow for 90% fewer compounds synthesized and halved development time compared to industry standards.

• Outcomes-based budgeting aligns capital allocation with milestone achievement and program conviction.

Financial guidance and capital allocation

• Annual guidance is provided, with significant updates tied to strategic changes; 2026 gross burn expected to be under $390 million, excluding partnership inflows.

• Partnership milestones are expected to provide meaningful non-dilutive capital.

• Portfolio management approach allows for dynamic reallocation of resources based on program progress.

• Opportunistic use of ATM has extended runway into early 2028.

• Focus on building a strong shareholder base and attracting biotech investors as more data becomes available.

Partnership landscape and competitive positioning

• Value realization from partnerships is prioritized over announcements, with over $500 million in upfront and milestones achieved.

• Roche and Sanofi partnerships provide significant milestone and royalty opportunities, with up to 15 programs for Sanofi and up to 40 for Roche.

• Integrated vertical AI tech stack and proprietary wet/dry lab capabilities differentiate the platform.

• Partnerships are structured to cover direct costs and build platform value without using internal capital.

• Industry remains largely untapped, with only 3% of the genome having approved drugs.